Literature DB >> 1518690

Mother-to-child transmission of human immunodeficiency virus type 1: risk of infection and correlates of transmission.

C Gabiano1, P A Tovo, M de Martino, L Galli, C Giaquinto, A Loy, M C Schoeller, M Giovannini, G Ferranti, L Rancilio.   

Abstract

One thousand eight hundred eighty-seven children born to human immunodeficiency virus type 1 (HIV-1) seropositive mothers, including 1045 infants prospectively followed up from birth, were studied. Intravenous drug use was the most frequent maternal risk factor, although the percentage of women infected by sexual contact increased from 5.8% in 1985 to 28.5% in 1990. Of the 551 first children followed up from birth and older than 15 months of age, 101 (18.3%) acquired infection and seroconverted to HIV-1. Another 31 (5.6%) asymptomatic seronegative children showed the presence of viral markers, for an apparent mother-to-offspring transmission rate of 23.9%. Overlapping results were seen in 22 second-born children followed up from birth. Of 59 sibships with definite infection status, when the first child was infected, 14 (40%) of 35 second children were infected, whereas when the first child was not infected, only 2 of 24 (8.3%) second children were infected. Discordance in HIV-1 transmission was found in 1 of 18 pairs of twins. Univariate and multivariate analyses of possible risk factors for HIV-1 transmission performed on the entire population of children and in the cohort of those followed up from birth were basically in agreement in indicating that the development of symptoms in the mother before delivery and breast-feeding (indeed adopted in only 22 infants in whom HIV-1 infection was identified at birth) were significantly and independently associated with a higher transmission rate. In addition, girls were more frequently infected than boys.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1518690

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  9 in total

1.  Care of the HIV-exposed child--to breast feed or not?

Authors:  Anju Seth
Journal:  Indian J Pediatr       Date:  2012-03-01       Impact factor: 1.967

2.  Inhibition of murine embryonic growth by human immunodeficiency virus envelope protein and its prevention by vasoactive intestinal peptide and activity-dependent neurotrophic factor.

Authors:  D A Dibbern; G W Glazner; I Gozes; D E Brenneman; J M Hill
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

Review 3.  Pediatric human immunodeficiency virus infection.

Authors:  J B Domachowske
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

Review 4.  Mother-to-child transmission of human immunodeficiency virus type 1.

Authors:  G C John; J Kreiss
Journal:  Epidemiol Rev       Date:  1996       Impact factor: 6.222

5.  Prenatal Screening for HIV in Nova Scotia: Survey of Postpartum Women and Audit of Current Prenatal Screening Practices.

Authors:  Mark Downing; Laura Youden; Beth A Halperin; Heather Scott; Bruce Smith; Scott A Halperin
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-07       Impact factor: 2.471

Review 6.  Evidence-based gender findings for children affected by HIV and AIDS - a systematic overview.

Authors:  Lorraine Sherr; Joanne Mueller; Rebecca Varrall
Journal:  AIDS Care       Date:  2009

7.  Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS.

Authors:  K K Van Rompay; M G Otsyula; M L Marthas; C J Miller; M B McChesney; N C Pedersen
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

8.  Maternal-infant HIV transmission and circumstances of delivery.

Authors:  L Kuhn; Z A Stein; P A Thomas; T Singh; W Y Tsai
Journal:  Am J Public Health       Date:  1994-07       Impact factor: 9.308

Review 9.  Growth and puberty in children with HIV infection.

Authors:  E S Majaliwa; A Mohn; F Chiarelli
Journal:  J Endocrinol Invest       Date:  2009-01       Impact factor: 4.256

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.